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HYBRID DATA-BASED MODELLING IN ONCOLOGY: SUCCESSES,
CHALLENGES AND HOPES
Ange´lique Ste´phanou1,*, Pascal Ballet2 and Gibin Powathil3
Abstract. In this opinion paper we make the statement that hybrid models in oncology are required
as a mean for enhanced data integration. In the context of systems oncology, experimental and clinical
data need to be at the heart of the models developments from conception to validation to ensure
a relevant use of the models in the clinical context. The main applications pursued are to improve
diagnosis and to optimize therapies.We first present the Successes achieved thanks to hybrid modelling
approaches to advance knowledge, treatments or drug discovery. Then we present the Challenges that
need to be addressed to allow for a better integration of the model parts and of the data into the
models. And finally, the Hopes with a focus towards making personalised medicine a reality.
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1. Introduction
Mathematical modelling in cancer is not new [47], however this fields truly exploded at the turn of the
millennium. But at that time, the immense majority of models aimed to decipher, highlight or explain some
mechanisms in relation to tumour growth, angiogenesis and invasion [22]. The link with experimental data was
scarce and essentially concerned the kinetics of growth. Progressively the models evolved in connection with two
major advances: the first concerned the increased computational ability of the machines that allowed to perform
simulations in the sense of numerical experimentations; the second concerned the progresses made in imaging
techniques that allowed a wider access to data. With time, the models progressively became more “informed”
meaning that they integrated experimentally measured parameters and were validated based on experimental (in
vivo or in vitro) observations. Whereas the model developers were mainly located in mathematical, computing
or engineering departments, it is now not rare to found them at the heart of hospital infrastructures.
As of today, models are massively used in the domain of cancer to pursue four main goals: to improve diagnosis,
to improve therapy, to identify and develop new drugs and to bring new knowledge on the development of the
disease. Those goals contribute to bring the models much closer to the clinic. Models are developed in the
context of Systems Oncology [61] which – as Systems Biology [69] – provides the comprehensive framework in
which cancer can be investigated to truly understand and link its many aspects from the depth of the genes to
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the host environment. Such an integrated approach requires hybrid models, i.e. models made of different sub-
parts heterogeneously defined mathematically to adequately describe various processes (biological, chemical,
physical, etc.) and events occurring at multiple spatio-temporal scales [66]. However rather than focusing only
on the hybrid aspect of the mathematical model formulation, we would like to extend the hybrid definition to
the integration of experimental data at the core of the models, since this implies new model developments of a
hybrid nature in its primary sense. This crucial integration is more and more emphasized [3, 5, 40, 41, 75, 76]. As
for multiscale integration, data integration requires specific model adaptation to accommodate heterogeneous
information and/or indirect information in the sense that the required ones are often unavailable [40].
This paper, advocating hybrid data-based modelling in oncology, is organized in three parts. First, we present
the Successes with some examples where mathematical modelling in general and hybrid modelling in partic-
ular proved useful in a clinical context. Then we will evoke the Challenges that computational biologists and
biomathematicians have to face to fully exploit the huge potential of modelling so as to make the models com-
monly used in the clinical practice to diagnose and treat patients. Finally we will describe the Hopes that the
new generation of hybrid models bear towards making personalised medicine a reality.
2. The successes
Mathematical oncology has now a proven track record: to understand, to predict, to optimize and to dis-
cover [5]. In this section, we present some few representative contexts in which mathematical models proved
particularly insightful and/or useful.
2.1. Prediction of cancer evolution
The first models in cancer essentially aimed at describing the growth kinetics of the tumours [47, 49]. Beyond
the simple description of growth, the models then developed to account for more detailed information such as
the shape of the tumour, the state of the tumour cells (proliferative, quiescent/dormant or necrotic), the nature
and state of the environment (vascularized, degraded, fibrous, hypoxic, acidic, etc.) and also to predict how all
these elements evolve when therapy comes into play [40]. As for now, it is difficult to find clinical studies for
which therapies have been defined or optimized from a mathematical model. It is most usual and widespread to
find models that retrospectively predict how the tumour would grow or explain why a therapy was successful or
failed. The obvious reason is that such experimentations on patients cannot be authorized since the risk remains
high and clinicians are not yet ready to trust a computer program. In the other hand, models are now accepted
in the clinic to predict the evolution of a tumour from patient images, to inform the clinician on the potential
outcome. One such example is given in Colin et al. [23], where temporal CT scans of a specific patient are used
to calibrate a mathematical model that proved successful in predicting the evolution of metastatic nodules in
the lung. In a similar way the study by Wang et al. [72] exploits magnetic resonance images (MRI) of patients
with glioblastoma to measure for each individual patient the net cell proliferation and invasive rates. Those
rates are then used in a mathematical model to evaluate the prognostic (survival time) for each patient. It has
to be noted that these two cases are both excellent examples of hybrid models that integrate information from
clinical images at their core.
2.2. Therapeutic optimization
The number of mathematical models dedicated to therapeutic optimization is enormous, however computer-
aided treatments at the bedside remain extremely limited as noted in [11]. The work accomplished towards
treatment optimization clearly paves the path to personalised medicine where treatments would be designed to
suit a specific patient by integrating all his/her characteristic from genetic to personal habits [69]. We will not
enter here into model presentations since this will be the main focus on the “Hopes” section. One interesting
example though is the case of chronotherapy whereby drug administration is adjusted to the circadian rhythms
[9]. This example is worth mentioning since clinical trials showed an existing benefits of chronotherapy for
cancer patients outcomes. At the same time, inter-patient variability was also exhibited. These findings advocate
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the necessity of personalised chronotherapeutics through integrated models. Those are thoroughly reviewed in
Ballesta et al. [9].
2.3. Identification of resistance to therapy
One important contribution of the mathematical models was in the identification of resistance mechanisms.
Passive resistance mechanisms for example could be involuntary exhibited in simulations while testing drug
delivery regimens. In these simulations, it occurred that the drug could bypass the tumour targets depending
on the structure of the vascular network [67]. More generally, modelling of the spatiotemporal availability of
drugs commonly show heterogeneous distribution in the tumour where portion of it might escape to treatment.
Similarly, and for the same reason of non optimal oxygen delivery, part of the tumour can become hypoxic
and the cell can enter into quiescence as a survival mean [68]. Through this mechanism, the cells can escape to
cytotoxic drugs since they stopped their cycle and limit the exposure to cytotoxic damages [60]. Active resistance
mechanisms have also been extensively modelled. Those mainly relate to the genetic and epigenetic alterations
that modify the cells vulnerability to the drugs and/or enhance its evasion power. We refer the interested reader
to the dedicated review by Foo et al. [29].
2.4. Identification of new drugs
The new drug candidates are first tested in vitro on cultured tumour cells where viability versus death is
measured in time for a range of drug concentrations. The dose is then scaled up for in vivo testing on animals
(mostly rodents) bearing the same tumour cells of interest. Finally clinical trials allow to test the drug on
patients to fully evaluate the drug efficacy as well as its potential side effects. At the end of this long process,
only a very small number of drugs are finally approved by the various agencies [38, 44] and even so the efficacy
often remain below expectations [25]. Mathematical modelling thus appears as a crucial tool for integrating in
vitro and in vivo and make sense of the results so as to favour a more informed and efficient transposition to
patients [21]. PK/PD models are commonly used and accepted in drug development to help in selecting the
best administration schedule, to avoid toxicity and to “unable decision making” [31]. However standard PK/PD
are often limited on their own since other crucial information might be needed to catch all aspects of the drugs
interaction with the overall system. In the very recent years PK/PD models were found to be coupled to other
model elements such as the cell cycle, the circadian rhythms [7], or the cell physiology which led to PBPK-PD
models (Physiologically-Based PK-PD) [7, 16, 21]. These couplings with detailed mechanistic models make it
possible to identify new therapeutic targets and to help design new innovative drugs [21].
3. The challenges
3.1. Integration of experimental and mathematical models
A mathematical or computational model is by essence always wrong in the sense that it can never entirely
describe and represent all aspects of reality. It is always based on assumptions made by the modeller and
is therefore strongly biased by the choices made. However this does not prevent models to produce accurate
prediction on some aspects of the reality. For example, the speed with which a tumour is growing, its shape or
its invasiveness can all be predicted based on some sets of relatively simple assumptions regarding proliferation
rate or cell-cell adhesion [32]. Similarly, and as we saw it in the previous section, the effects of different types
of therapy can also be assessed with a good accuracy and can include the prediction of resistance [29, 37] or
relapse effects [30, 43]. Phenomenological models – that is models that implement a predetermined answer for a
phenomena given an entry condition or stimulus – often proved sufficient to make good qualitative predictions.
For example to model the effect of a drug, it can simply be assumed that if the cells are subjected to a threshold
concentration of drugs then it will enter apoptosis [60]. In the other hand the explicit description of the mode of
action of the drug can be modelled through mechanistic pharmacodynamic models [8]. This option is favoured
to understand how the drug truly works and how its effect can potentially be enhanced by identifying some best
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suited conditions of administration or applicability. Phenomenologic or mechanistic, it is the utility and power
of the model to answer the specific questions for which it has been built that matters the most. However in the
context of cancer, and more specifically in the domain of drug testing, it is essential to integrate biological data
at the heart of the computational model development to guide the choice of pertinent hypotheses and ensure
the model validity to describe key observations. We indeed recall that it is illusory to search for model genericity
– since each model serves its own purpose – but in the other hand it should be tailored to provide real insights
to truly advance knowledge and to be immediately useful especially towards personalised medicine.
There is indeed a critical need for models truly rooted in reality (i) so as to be relevant for a clinical use,
(ii) to cope with the high rate of failed clinical trials in the last remaining stages of drug testing [44]. The
enhanced integration between pre-clinical models (in vitro and in vivo) with more informed mathematical
models (in silico) would lead to a much higher level of confidence, however efforts in that direction are still rare.
This coupled in vitro/in vivo/in silico approach was already attempted by [74] back in 2012 and was further
advocated in [16] with the example of Physiologically-based pharmacokinetic and pharmacodynamic models
(PBPK/PD).
3.2. Management of the rising computational cost
Hybrid modelling directed towards simulating the rise and development of cancer requests high computational
power. What is generally costly is:
– the integration of the many interacting phenomena occurring at different time and space scales. This
requires specific algorithms to order the simulations for the different events sequentially [48, 60]. Time
can be wasted since some events are on hold while other needs to reach stationary states for example.
Moreover each event is generally solved with its own grid size and granularity from continuous to discrete
[34]. This is however amenable to parallel computing.
– the simulation of a high number of cells, up to the million, since most models now describe the real 3D
geometrical context and environment to account more faithfully to reality by avoiding geometrical biased
[36].
– the integration of the tumour environment including other cell types (fibroblasts, immune or stem cells,
etc.), the extracellular matrix and the tissue vasculature. This requires multiphysics modelling to account
for the mechanical properties of the matrix or the blood flow through the vessels.
– the graphical representation of the running simulation. This aspect can be very useful especially in the
conception phase of the code. It allows to see the developing tumour and to image the variables that
characterize the environment so as to see if they are correctly integrated. This also allows to stop the
simulation – while testing some parameters for example – if inappropriate or deviant behaviours occur.
– the integration of experimental data. Since, as we saw it in the previous section, the new generation of
hybrid models is to merge pre-clinical data in the in silico model in a dynamic way. For example the
data can serve as check points during the simulations (for validation) or can be provided and processed
iteratively (scan images for example) so as to adapt a target trajectory for treatment optimality.
Of course not all models need to integrate all of these items, but the most recent hybrid models usually integrate
at least one of them and each are computationally demanding on their own. It has to be noted that for most
of these items there exists dedicated softwares, to solve multiphysics problems (e.g. Comsol multiphysics),
mechanical issues (e.g. Ansys), to deal with image processing on the fly (e.g. ImageJ), to graphically represents
the variables while simulating (e.g. Paraview). Interfacing such different softwares could appear useful but in
practice this can be very complicated not only for the implementation, but to maintain the workability of the
overall code since it is required to cope with the many updates and releases of the individual softwares. Those
can compromise their compatibilities and threaten the code sustainability on the long run. Moreover calling for
multiple sub-codes and softwares generally takes too much machine time (RAM). This option is therefore not
adapted and we are left with the necessity of recoding everything in an integrated and consistent framework.
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3.2.1. Some solutions
Although there is room to produce optimized algorithms, the best hope to cope with the rising computational
costs involved in hybrid cancer modelling is to exploit the progress made in computer hardwares and processors.
The computing power of the machines – that continues to grow exponentially – have been significantly enhanced
over the last ten years with the appearance of the first multicore processors. Those allowed to overcome the
stabilization (below 5 GHz) of the clock speed of the single processor [10]. However, the graphics cards have
today the highest computing power thanks to their massively parallel processor architecture of up to a thousand
calculus units. They are programmable thanks to general purpose language close the C language like Cuda
or OpenCL and can be used to compute parallel-structured algorithms. Quantum computing could be the
next breakthrough to drastically improve the computing speed, although the applicability mostly concerns
combinatory calculus [10].
Coping with the simulation time is a real issue to address since the all goal of cancer modelling is to help
in providing a faster and more accurate diagnosis and/or to help in defining the optimum treatment strategy.
The models are thus designed to be used in the clinical context and as such – once fed with the data from the
patient – they should provide an (almost) immediate answer to be approved as a clinical assistant.
3.3. Need for software tools for research and education
Given the increased complexity of the hybrid models, advanced computational skills become more and more
essential in particular for those who wish to fully exploit the new hardware architectures. However, the main
interest for a biomathematician or computational biologist is to focus on the modelling activity which is to
define some work hypotheses to put under the test by identifying the key phenomena and the main actors
(variables) of the subject of study. The time spent on the implementation of the model, i.e. on coding, should
not overcome the time spent on developing the model.
Fortunately many efforts have been made over the last 10 years to develop integrated computing environment
that are open-source and free so as to be re-used and shared. Those environment dedicated to multicellular
modelling all allow to implement easily basic cell properties, such as migration, adhesion and proliferation as
well as reaction–diffusion dynamics of chemicals. We here focus on the presentation of a few of them among
those which proved particularly useful to model tumour growth and the effects of therapies and whose used
is widespread and acknowledged in the cancer modelling community. All are suitable for multiscale modelling,
they allow to make 3D simulations and they all integrate a graphic interface to display the simulations.
3.3.1. CompuCell3D [70]
This software is based on the Cellular Potts Model (CPM) [35]. It allows to describe the evolution of cells,
where each cell is defined by a collection of sub-elements of a square grid. An energy function (Hamiltonian) that
includes adhesion energies and volume constraints is evaluated. If the energy is minimized the cell configuration
can be changed. Add-ons on the main software allow to integrate the intracellular dynamics [4]. Model imple-
mentation is flexible and can easily be performed by non-experts in coding by defining the model in an XML
file. More experts users can produce their own code using the Python language and developers can even create
their own plugins using the C language [10]. This framework has been extensively used to study angiogenesis
[55] but also to study therapy issues such as the routes of drug delivery [73] or bystander effects in radiation
therapy [62].
3.3.2. Cell-based Chaste [53, 58]
This is an efficient software in the sense that virtually anything can be modelled from regulation networks,
to mechanical constraints. The implementation is based on three interlinked modules: (1) a cellular behaviour
module allowing the intrinsic cell evolution (through its cycle for example), (2) a module for cell movement
and mechanical interactions, (3) a module for the transport of substances (molecules for example). A recent
useful add-on is specifically dedicated to the modelling of microvessels [36]. The strength of this software lies in
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its flexibility allowing lattice-free implementations as well as lattice-based approaches including the CPM. Its
use however requires to possess more advanced computing skills than for CompuCell3D1 but in the other hand
it is well adapted to merge to the platform some pre-existing codes which can favour the adhesion of a wider
modelling community. Although Cell-based Chaste2 was initially developed to model colorectal cancers [71], it
can potentially be applied to any type of cancers including non-solid tumors.
3.3.3. PhysiCell [33]
PhysiCell3 stands for physics-based multicellular simulator. It is an agent-based simulator written in C++
and parallelized with OpenMP so as to simulate up to a million of cells. It integrates different solvers to describe
the biochemical environment (from diffusing substrates to cell-secreted signals) as well as the cell–cell mechanical
interactions. Paraview is chosen for data visualization. It is still a young platform but conceived to evolve with
the emerging new needs. One strength of the platform is that it is sufficiently flexible for replicating results
from other simulators which – as Chaste – favours the migration of existing codes to this platform. Another
advantage of the software is to put forward the possibility of a direct integration of experimental data file by
using annotated experimental or clinical image as inputs to the software (although not implemented yet).
3.3.4. SimCells [10]
This software has been specifically developed to exploit the multiprocessor architecture of GPU. The number
of simulated cells thus depends on the number of units of the GPU. It can reach the million with the most recent
graphic cards. The cells in SimCells4 are defined as off-grid agents. A graphical user interface enables the user
to define its systems with cells of different types whose behaviours are determined through the parametrization
of predefined sets of rules and/or properties (such as adhesivity or motility) under the form of Conditions
then Actions. One advantage of the software is to give the ability to stop and restart the simulations so as to
modify some parameters or conditions on the fly. The software is thus very useful to rapidly test some simple
ideas without requiring any coding expertise. It is consequently an excellent tool for non expert in coding and
proved particularly useful as a pedagogic tool to initiate a wide (diverse) audience to model development. The
main drawback of the software for now is that it does not allow to represent the intrinsic physical/mechanical
properties of the simulated objects. Moreover experimental data measurements can not be integrated since the
definition of behaviours is essentially based on probabilities rather than on physical parameters, meaning that
quantitative information cannot be reached. This is currently restraining the use of the software, however it
remains a very useful numerical test bench, i.e. a good virtual platform for numerical bio-experimentations.
4. The Hopes
4.1. Making personalised medicine a reality
In a not too far future, the patient scans, analyses and medical history will feed a computer program.
The MRI (or other scans) will be automatically analysed, the tumour volume evaluated, etc. All information
provided will be cross related and an accurate diagnosis would be made based on the currently developing deep
learning algorithms where the computer will be trained to acquire a knowledge equivalent to this of a thousands
of clinicians with different expertise altogether (radiologists, oncologists, neurologists, etc.) [57]. Beyond the
diagnosis, the patient’s data will be used to create the patient’s virtual tumour i.e. a numeric clone with the
exact same location and properties (shape, volume, nature, grade, metabolic state, etc.) so as to behave as
the real tumour. Given the knowledge of the possible therapeutic means and of the usable drugs, simulations
would then been made using the virtual tumour to identify the optimum treatment in terms of means of action,
1http://www.compucell3d.org/
2http://www.cs.ox.ac.uk/chaste/
3http://physicell.mathcancer.org/
4http://virtulab.univ-brest.fr/simcells.html
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Figure 1. The concept of personalised medicine. A virtual tumour is created from the patient
data (scans/medical file/state) and is used to identify the optimum treatment and its schedule
to cure or to maximize the life expectancy. All data acquired on the patient during the course of
treatment is used to feed the virtual tumour and to update /adapt the therapy while respecting
some imposed constraints (so as to control therapeutic interactions, to avoid contraindications
with other pathologies, to take into account the patient state).
dosage and planning of drug administration. Treatment adaptations during the course of treatment can be made
by updating the virtual tumour with the newly available patient data. It is expected that such a clinical tool
would produce at the same time a highly informed (hence accurate) diagnosis and the best adapted therapeutic
strategy that would maximize the chances to cure the patient or to significantly extend the survival (by fully
exploiting the current knowledge in oncology). Beyond the benefit to the patients, such a tool would help to
standardize and optimize the screening procedures to make them more efficient so as to gain time to obtain a
diagnosis and to start the treatment.
The realization of such a tool requires a level of integration of highly heterogeneous biological data in multiple
space and time scales, as illustrated in Figure 1, making it a complex problem to address. However, current
developments in computational, mathematical and systems oncology [1, 2, 6, 11, 20, 26, 28, 39, 42, 51, 59, 61, 69]
show great potential to develop predictive, personalised clinical cancer practice, integrating mathematical and
computational approaches with traditional bench and clinical experiments. Moreover, the availability of a vast
amount of patient-specific data with the help of technical and computational advances can further help in devel-
oping such in silico framework/tool. Karolak et al. [42] gives an excellent review on various mathematical models
that address tumour development, progression and response to treatments. Recently, there are several attempts
and applications towards this direction, incorporating the complexity of tumour evolution and treatment efficacy
in multiple scales [11, 20, 39, 42, 50, 51, 59, 61, 69]. Such models allow for intratumoural cross-scale integra-
tion of intracellular, extracellular and intercellular concepts, providing comprehensive modelling frameworks to
which patient-specific information can be added to devise personalised therapeutic protocols.
Macklin et al. [50, 51] introduced a patient-specific calibration method based on a hybrid agent based model to
fully constrain the model based upon clinically-accessible histopathology data to obtain a patient histopathology
providing new insights on the biophysical underpinnings of cancer. This may in future pave the way to augment
a patient’s imaging data with well calibrated models to predict optimal surgical margins based upon the patient-
specific imaging data. Cook et al. [24] used a biologically driven discrete hybrid cellular automaton (HCA) model
of bone metastatic prostate cancer to obtain an optimal therapeutic window for putative targeted therapies as
current pre-clinical models were limited in predicting the therapeutic effects. They used it to study the effect of
TGFβ inhibitor treatment on the evolution of the cancer. Ste´phanou and co-workers [20] proposed the design
of a patient-specific virtual tumour incorporating angiogenesis, matrix remodelling, hypoxia, and cell state
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heterogeneity that will all influence the tumour growth kinetics and degree of tumour invasiveness. They have
used a hybrid, multiscale approach for its implementation with the help of the pre-clinical data acquired on a
mouse model as a proof of concept. By combining image analysis and physiological modelling, they have shown
that the simulated virtual tumour matches the characteristics and spatiotemporal evolution of the real in vivo
tumour, showing the potential use of experimentally motivated computational and mathematical models in
personalised therapeutic delivery. In a similar approach, Powathil et al. [19, 61] used a hybrid multiscale cellular
automaton framework with intra- and inter-cellular dynamics to model tumour progression and further used
to study the optimal combination of multimodal therapies. They have validated the model with experimentally
estimated parameters for multiple cell-lines and their framework claims flexibility for modelling multimodality
treatment combinations in different scenarios [19]. Volpert et al. proposed another example of hybrid approaches
to investigate blood related diseases including Leukemia [46], Multiple Myeloma [17, 18] and Lymphoma [28]
in order to test, interpret or predict the effects of treatments in relation to clinical data. Such experimentally
calibrated and validated multiscale frameworks not only take us a step closer to personalised medicine but also
helps as in silico test-bases for potential drug discovery and to study and test potential hypotheses to optimise
multimodality therapeutic protocols before taking its clinical delivery.
In addition to such hybrid multiscale approaches, there are other mathematical models in the literature with
a top-down approach to devise personalised cancer therapies. Swanson and co-workers [6, 39, 52] use patient-
specific mathematical models based on continuum mathematical modelling approaches to deliver patient-specific
treatment predictions in neuro-oncology to treat very aggressive malignant brain tumours. Enderling lab [59, 63]
developed mathematical model that use the concept of proliferation saturation index to predict patient specific
radiotherapy protocols and they claimed that with the help of mathematical models, the information gained from
radiobiological images can be used to select personalised RT dose-fractionation protocols. Ballesta et al. [7] used
a multiscale modelling approach, informed by in vitro to preclinical studies to develop cell line specific model
to optimise anticancer therapies. Kronik et al. [45] proposed a general mathematical model for prostate cancer
immunotherapy, incorporating vaccine interactions and immune system and validated the predictions using the
results of a clinical trial data, showing its potential applications in personalised immunotherapy protocols.
These are some examples of several computational and modelling approaches to potentially deliver per-
sonalised multimodality therapeutic protocols in the fight against cancer. With the advancement of tissue
engineering and the concept of “organ on chips” [27, 56], parameterisation, calibration and the validation of
developing in silico tools can be achieved in a little more realistic scenarios and thus helping to move steps
closer to providing patient-specific treatment delivery tools.
4.2. Deciphering the roots of the disease
Beyond the interest for developing more efficient therapies, hybrid modelling in cancer can also prove essential
to tackle more fundamental issues such as the questioning of the origin of cancer. An ongoing discussion concerns
the Tissue Organization Fields Theory (TOFT) [64, 65] which is opposed to the classical Somatic Mutation
Theory (SMT) [13–15, 54]. The TOFT argues that a loss of tissue homeostasis following carcinogenic stresses
releases the constraints on cell proliferation and motility. On the other hand, the SMT is based on the mainstream
understanding that mutations directly drives cancer development. When they do not lead to cell apoptosis then
more mutations can accumulate ultimately resulting in a deviant cell behaviour. If the latter is not spotted by
the immune systems, then a malignant tumour can develop.
Determining which theory is right can have enormous consequences in the way with which cancer is treated.
In the SMT the cell is the cause and this justifies the use of most standard therapies that directly targets the
tumour cells (cytostatic or cytotoxic molecules, radiation, surgery). In the other hand in the TOFT the cell is not
the cause and the main focus should be to work on the environment and try to restore its normal (homeostatic)
properties. This means that most therapeutic strategies need to be rethought accordingly to avoid a snow ball
effect whereby therapy would be participating in a faster and more aggressive development of the disease.
Systems oncology and its hybrid modelling tools provide the means to fully investigate this delicate issue
since it directly relates genotypic changes to tissue disregulation [12]. The question is: is it from bottom to top
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(SMT) or from top to bottom (TOFT)? As far as we know, no theoretical models (i.e. simulation based) have
been tacking this issue yet. Although we can imagine some ways to test this, using the same model hypotheses
concerning differentiation and growth while testing alternatively (1) the effect of spontaneous mutations; (2) the
loss of tissue homeostasis and its consequences on the cell behavioural divergence (phenotypic and genotypic).
In both case, the evolution of the cells fitness (towards proliferation, migration or apoptosis) could be compared
as a criterion for cancer progression.
5. Conclusion
We now enter the era of Artificial Intelligence where humans are assisted or replaced by machines for inter-
pretation and decision tasks that would lead to more accurate diagnosis and more efficient therapies. Without
necessarily realizing it, we – as biomathematicians, computational biologists, bioinformaticians and statisticians
– are the main actors of this transition and evolution. The challenge for us is to build the theoretical tools that
will make the machines able to process the information and produce interpretations that will condition deci-
sions and actions. In this context of systems oncology, the new generation of models needs to be more and more
integrated to process both imaging data and “big data” (i.e. genomics, proteomics and other omics). Again,
this calls for hybrid modelling to couple statistical models and deep learning algorithms for recognition and
interpretation tasks with mechanistic models for knowledge-based predictions. These two modelling approaches
– statistic and mechanistic – belong to two different scientific communities. One of the big challenge is to make
them deeply interact so as to make personalised computer-assisted therapy a clinical reality.
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